The share price of HTG Molecular Diagnostics, Inc. [NASDAQ: HTGM] inclined by $0.80, presently trading at $0.74. The company’s shares saw 4.20% gains compared to the lowest price in the period of the last 52 weeks, set at $0.71 recorded on 09/19/19. The last few days have been tough to the share price as HTGM fall by -5.86% during the last week, even though the stock is still down by -15.91% compared to -0.05 of all time high it touched on 09/17/19. However, the stock had a poor performance during the past 3 months, roughly losing -17.36%, while additionally dropping -80.54% during the last 12 months. HTG Molecular Diagnostics, Inc. is said to have a 12-month price target set at $4.80. That means that the stock has a strong potential to acquire 4.06% increase from the current trading price.

HTG Molecular Diagnostics, Inc. [NASDAQ:HTGM]: Analyst Rating and Earnings

Its stock price has been found in the range of 0.71 to 5.46. This is compared to its latest closing price of $0.80.

Stay on the lookout for the next quarterly financial report – the company is expected to release the following results on Thu 14 Nov (In 55 Days).

Fundamental Analysis of HTG Molecular Diagnostics, Inc. [HTGM]

Now let’s turn to look at profitability: with a current Operating Margin for HTG Molecular Diagnostics, Inc. [HTGM] sitting at -79.88 and its Gross Margin at +76.33, this company’s Net Margin is now -80.00%. These metrics indicate that this company is not generating as much profit, after accounting for expenses, compared to its market peers.

This company’s Return on Total Capital is -79.05, and its Return on Invested Capital has reached -43.00%. Its Return on Equity is -182.49, and its Return on Assets is -50.61. These metrics suggest that this HTG Molecular Diagnostics, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.

Turning to investigate this organization’s capital structure, HTG Molecular Diagnostics, Inc. [HTGM] has generated a Total Debt to Total Equity ratio of 79.04. Similarly, its Total Debt to Total Capital is 44.15, while its Total Debt to Total Assets stands at 38.09. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is -19.05, and its Long-Term Debt to Total Capital is 72.92.

What about valuation? This company’s Enterprise Value to EBITDA is -0.51. The Enterprise Value to Sales for this firm is now 0.38, and its Total Debt to Enterprise Value stands at 0.30. HTG Molecular Diagnostics, Inc. [HTGM] has a Price to Book Ratio of 3.44.

Shifting the focus to workforce efficiency, HTG Molecular Diagnostics, Inc. [HTGM] earns $200,971 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 3.78 and its Total Asset Turnover is 0.66. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 5.23 and its Current Ratio is 5.42. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.

HTG Molecular Diagnostics, Inc. [HTGM] has 29.34M shares outstanding, amounting to a total market cap of $23.47M. Its stock price has been found in the range of 0.71 to 5.46. At its current price, it has moved down by -86.45% from its 52-week high, and it has moved up 4.20% from its 52-week low.

This stock’s Beta value is currently 1.59, which indicates that it is 8.80% more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 26.89. This stock, according to these metrics, is currently Oversold.

Conclusion: Is HTG Molecular Diagnostics, Inc. [HTGM] a Reliable Buy?

HTG Molecular Diagnostics, Inc. [HTGM] stock is presenting a less attractive investment opportunity when compared to similarly-sized corporations in the same industry. The price performance of these shares has not shown much promise, and the financial results that this company has recently delivered present a highly risky investment.